TYK Medicines, Inc. Class H ( (HK:2410) ) has provided an announcement.
TYK Medicines, Inc announced positive results from its Phase II clinical trial of TY-9591, a tyrosine kinase inhibitor, against osimertinib for treating brain metastases from lung cancer with EGFR mutations. The trial demonstrated that TY-9591 showed significant statistical and clinical superiority over osimertinib, with a favorable safety profile and strong results across various patient subgroups. The company plans to submit a New Drug Application to the National Medical Products Administration, indicating potential advancements in treatment options for patients and a strengthened position in the oncology market.
More about TYK Medicines, Inc. Class H
TYK Medicines, Inc is a pharmaceutical company based in the People’s Republic of China, specializing in the development of tyrosine kinase inhibitors for treating brain metastases from lung cancer with EGFR mutations. The company focuses on innovative cancer treatments and has been conducting clinical trials to establish the efficacy of its products.
YTD Price Performance: -35.10%
Average Trading Volume: 282,830
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: HK$11.21B
See more insights into 2410 stock on TipRanks’ Stock Analysis page.